All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Gautam M. Borthakur, MD Anderson Cancer Center, Houston, US. We asked: Does the improvement in relapse-free survival after FLAG-IDA + gemtuzumab ozogamicin (GO) come at the cost of more severe toxicities in patients with core binding factor acute myeloid leukemia (CBF AML)?
Gautam Borthakur discusses the best regimens for the treatment of CBF AML, he explains FLAG-IDA based regimen gives a good patient outcome and he questions the associated toxicities that come from the addition of GO to the regimen. He then explains the FLAG-IDA + GO has proven efficacious such as better patient responses, including higher rates of relapse-free survival and MRD-negativity.
Does the improvement in RFS after FLAG-IDA + GO lead to more severe toxicities in CBF AML?
FLAG-IDA for acute myeloid leukemia
Summary of two abstract presented at ASH 2019 focusing on the FLAG-IDA regimen for the treatment of AML.
Revised Canadian consensus guidelines for diagnosis and treatment of elderly patients with AML – Comments from Andre Schuh
Revised clinical practice guidelines for the management of Acute Myeloid Leukemia (AML) in patients age 60 years
Subscribe to get the best content related to AML delivered to your inbox